Copies of letters sent to healthcare professionals in December 2012, to inform of new safety information and advice:
| Date sent | Medicine | Safety information |
|---|---|---|
| 3 December 2012 | Sprayable Evicel fibrin sealant (94Kb) |
Risk of life-threatening air embolism. |
| 10 December 2012 | Lapatinib (Tyverb) (674Kb) |
Lapatinib combined with capecitabine has poorer efficacy compared with trastuzumab combined with capecitabine. |
| 10 December 2012 | Lenalidomide (Revlimid) (38Kb) |
Risk of hepatic disorders – routine monitoring of liver function, and dose adjustments in patients with renal impairment, are recommended. |